Please do not leave this page until complete. This can take a few moments.
Veristat, a clinical research organization headquartered in Southborough, has appointed Rachel Page as its new chief commercial officer.
Page will assist biopharmaceutical companies in navigating clinical and regulatory challenges to speed the delivery of innovative therapies, according to a press release by Veristat on Thursday.
With more than two decades of experience in the clinical and pharmaceutical industry, she will oversee Veristat’s commercialization strategy and operations, as well as focusing on the growth and development of the commercial team.
Page was previously a chief commercial officer for CTI Clinical Trial and Consulting Services in North Carolina, according to her LinkedIn. She held several similar positions at Pennsylvania-based Clario, a contract research organization specializing in clinical services and customizable medical devices.
"I am thrilled to join this dynamic, science-driven team," Page said in the press release. "Veristat is exceptional at facilitating the delivery of crucial therapies and transforming client operations. I am honored to collaborate with such a passionate group of executives, colleagues, and clients who are dedicated to accelerating the availability of groundbreaking treatments for patients with complex conditions. "
Page received a bachelor of science degree in social and management sciences at Edinburgh Napier University in Scotland, according to her LinkedIn. She succeeds Cindy Henderson, who has transitioned to become chief strategy officer for the company.
Veristat, founded in 1994, integrates full service clinical trial execution, regulatory affairs and safety and strategic advisor services to advance complex therapies. In addition to its Southborough headquarters, Veristat has locations in North Carolina and other countries including France, Spain, Switzerland, United Kingdom, India, and Taiwan.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments